Bicara Therapeutics Reports Reduced Net Loss in Q3

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 10 2025

0mins

BCAX-3.76%

Should l Buy BCAX?

Source: Yahoo Finance

Q3 Financial Performance: Bicara Therapeutics (BCAX) reported a Q3 net loss of $0.67 per diluted share.
Loss Comparison: The loss has narrowed compared to previous periods, indicating potential improvements in financial performance.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BCAX?" and start using high-conviction signals backed by rigorous historical data.

BCAX

$16.37+Infinity%1D

Analyst Views on BCAX

Wall Street analysts forecast BCAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCAX is 30.44 USD with a low forecast of 11.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Analyst Rating

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 17.010

Low

11.00

Averages

30.44

High

48.00

Current: 17.010

Low

11.00

Averages

30.44

High

48.00

Citizens

initiated

$31

2026-01-29

Reason

Citizens

Price Target

$31

AI Analysis

2026-01-29

initiated

Reason

Citizens initiated coverage of Bicara Therapeutics with an Outperform rating and $31 price target. The firm says the company's ficerafusp alfa, in combination with pembrolizumab, has delivered "standout efficacy" in HPV-negative head and neck squamous cell carcinoma. The analyst says Bicara shares represent an attractive investment opportunity, with 40% potential downside in a bear case and 210% potential upside in a bull case.

Mizuho

Joseph Catanzaro

Neutral

initiated

$18

2025-12-17

Reason

Mizuho

Joseph Catanzaro

Price Target

$18

2025-12-17

initiated

Neutral

Reason

Mizuho analyst Joseph Catanzaro initiated coverage of Bicara Therapeutics with a Neutral rating and $18 price target. The firm believes the company's ficerafusp alfa is unfavorably positioned in an "increasingly competitive" head and neck cancer landscape. Comparisons with cetuximab indicates little efficacy contribution from ficerafusp's TGF beta trap, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BCAX

Unlock Now

About BCAX

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa

Dec 06 2025Globenewswire

Efficacy Data Presentation: At the ESMO Asia Congress, Bicara Therapeutics presented preliminary data showing a 57% confirmed overall response rate for 750mg ficerafusp alfa combined with pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential for treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma.
Safety Analysis: The safety profile of the 750mg dose was consistent with the known safety of ficerafusp alfa plus pembrolizumab, demonstrating good tolerability in clinical applications and providing confidence for further research.
Dose Optimization Plan: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing clinical trial progress and aiming to accelerate the approval process for this therapy.
TGF-β Inhibition Impact: Data from the 1500mg dose showed greater TGF-β inhibition, with a median depth of response of 82% compared to 63% for the 750mg dose, suggesting that higher doses may lead to more durable clinical outcomes, addressing the urgent need for effective treatments among patients.

Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study

Dec 06 2025Newsfilter

Clinical Trial Progress: Bicara Therapeutics presented preliminary data at the ESMO Asia Congress showing a 57% confirmed overall response rate for 750mg Ficerafusp alfa combined with Pembrolizumab, with 10% of patients achieving a complete response, indicating significant potential in treating HPV-negative recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
Dose Optimization Strategy: The data suggest that the 1500mg dose of Ficerafusp alfa achieves greater TGF-β inhibition in the tumor microenvironment, resulting in a median depth of response of 82%, compared to 63% for the 750mg dose, providing strong support for pursuing accelerated approval.
Safety Analysis: The safety profile of 750mg Ficerafusp alfa in combination with Pembrolizumab was consistent with known safety data, demonstrating good tolerability and enhancing confidence in this treatment regimen.
Future Outlook: Bicara plans to declare the optimal biologic dose for the FORTIFI-HN01 study in the first quarter of 2026, further advancing the clinical development of this therapy to meet the urgent market demand for effective treatment options.

Bicara Reports Ficerafusp Alfa Clinical Data, 57% Response Rate at 750mg Dose

Dec 01 2025Newsfilter

Clinical Trial Progress: Bicara Therapeutics reports a 57% objective response rate for 750mg of ficerafusp alfa combined with pembrolizumab in the Phase 1b expansion cohort for 1L HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, indicating significant therapeutic potential.
Safety Analysis: The safety profile of this combination aligns with known characteristics of ficerafusp alfa and pembrolizumab, enhancing confidence in its clinical application and potentially accelerating FDA approval processes.
Conference Presentation: Bicara will present these preliminary data at the European Society for Medical Oncology Congress on December 6, 2025, further elevating the company's visibility and influence in the biopharmaceutical sector.
Market Demand: Given the treatment needs of head and neck squamous cell carcinoma patients, the development of ficerafusp alfa not only addresses a critical market gap but also has the potential to improve patient quality of life, meeting the growing demand for effective therapies.

Reassessing Biotech Pipelines: The Valuation Indicator Investors Have Anticipated

Nov 20 2025Globenewswire

Fair-Value Remeasurement Importance: Fair-value remeasurements under U.S. GAAP are becoming essential for late-stage biotech companies, providing insights into the financial implications of scientific advancements and enhancing shareholder value.
Oncotelic's Valuation Milestone: Oncotelic Therapeutics is set to undergo a significant fair-value remeasurement of its 45% stake in GMP Bio, with a new valuation indicating a potential asset value of approximately $765 million, reflecting progress in its oncology-focused pipeline.
Advancements in Clinical Programs: Oncotelic's pipeline includes multiple late-stage oncology and rare disease programs, with significant milestones achieved, such as advancements in OT-101 for pancreatic cancer and other promising candidates targeting various conditions.
Nanomedicine Market Growth: The valuation of Oncotelic's Deciparticle nanomedicine platform is tied to the growing market for nanomedicine, projected to exceed $350 billion by 2032, highlighting the potential for substantial financial recognition as clinical developments progress.

Wells Fargo Keeps Equal-Weight Rating on Bicara Therapeutics and Increases Price Target to $11

Nov 11 2025Benzinga

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
Exclusive Content: The platform features exclusive stories and insights generated by Benzinga reporters, catering to serious traders looking for an edge in the market.
Community Engagement: Over 10,000 traders are part of the Benzinga Pro community, emphasizing the platform's popularity and reliability among serious market participants.
Market Winning Strategy: The service is designed to help traders win in the markets every day by delivering timely and accurate stock market information.